News | November 10, 2021
Pulmatrix resolves dispute with Cipla
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
FDI increased 98% year on year in 2020 and pharma exports grew by 18% in the last financial year
It is the first presbyopia-correcting lens implant for cataract surgery
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age
Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The company to receive upfront and milestone payments, in addition to royalties
Subscribe To Our Newsletter & Stay Updated
